Nurix Therapeutics Inc (NRIX) Stock Price, Quote & News

Company Profile

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BT...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 660 5320

Fax: 415 525 4200

Website: www.nurixtx.com

Address:

1700 Owens Street, Suite 205, San Francisco, United States

Wigglyick Nov. 14 at 10:56 PM

$NRIX Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. It engages in the business of discovering, developing, and commercializing innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. Took a starter today. Daily & weekly charts

1 · Reply

ellajenkins Nov. 14 at 11:57 AM

New surprise entrant to STAT6 party in atopic dermatitis⤵️ $PFE on Nov 4 3Q earnings call disclosed they have a STAT6 inhibitor and already entering Phase 2b, "potentially first-in-class oral." Impactful for $KYMR $NRIX and others in space, I have to update list

0 · Reply

LongTrainRunning Nov. 13 at 4:57 PM

$NRIX this thing is all over the place lately! I'm done accumulating. Now I'll just sit back and wait patiently for a couple of years and do some call trades in the meantime.

1 · Reply

Stmkr Nov. 12 at 3:28 PM

$PRLD $CCCC $NRIX DACs the next big thing in oncology

1 · Reply

SuperGreenToday Nov. 12 at 8:42 AM

$NRIX Share Price: $12.85 Contract Selected: Apr 17, 2026 $10 Calls Buy Zone: $3.52 – $4.35 Target Zone: $5.89 – $7.19 Potential Upside: 58% ROI Time to Expiration: 155 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

oaksapollo Nov. 8 at 12:37 AM

$NRIX https://www.nurixtx.com/wp-content/uploads/2025/11/NX-1607-Translational-Insights-From-a-First-in-Human-Study-of-an-Oral-CBL-B-Inhibitor-in-Advanced-Solid-Tumors.pdf Love to see this. NX-1607 is like a silver bullet. It hits this very specific target and the result is broad-based immune activation. I know the efficacy is not there yet, but mark my words, this will be an important drug. It's early days. Need to figure out the dose, the frequency of dosing, potential conmeds, etc.

0 · Reply

nspyre Nov. 7 at 3:19 PM

$NRIX clinical data: IT WORKS! market: DUMP IT 5%!!!!!!!!

1 · Reply

oaksapollo Nov. 5 at 4:45 PM

$NRIX Fidelity 11.5% stake https://ir.nurixtx.com/node/11661/html

2 · Reply

FranciscoJavier2 Nov. 5 at 2:15 AM

$NRIX The positive surprise with NX-1607 at ESMO was fantastic, but don't lose sight of the main event. The next major catalyst is the bexobrutideg update at the ASH conference in December. We'll be looking for maturation of the durability of response data. Strong follow-up data will be the final green light heading into the pivotal program. The momentum is clearly building into year-end.

1 · Reply

FranciscoJavier2 Nov. 5 at 2:13 AM

Let's talk financials. The main bear argument earlier this year was the cash burn. Management has now provided a clear cash runway into H1 2027, fully funding the move into pivotal trials. This was achieved through a smart partnership model that continues to deliver non-dilutive cash (Gilead, Sanofi milestones). This team has a track record of "promise made, promise kept." Execution is everything, and they are executing flawlessly. $NRIX

1 · Reply

Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors

Nov 7, 2025, 9:00 AM EST - 9 days ago

Nurix Therapeutics Presents New Translational Data from First-in-Human Clinical Trial of Oral CBL-B Inhibitor NX-1607 Demonstrating Immune Activation and Tumor Microenvironment Remodeling

Nov 3, 2025, 9:00 AM EST - 13 days ago

Nurix Therapeutics Announces Presentations at the 67th American Society of Hematology (ASH) Annual Meeting

Oct 30, 2025, 7:00 AM EDT - 17 days ago

Nurix Therapeutics to Participate in Upcoming Investor Conferences

Oct 27, 2025, 7:00 AM EDT - 20 days ago

Nurix Therapeutics Announces Closing of $250.0 Million Registered Offering of Common Stock

Oct 22, 2025, 6:53 PM EDT - 25 days ago

Nurix Therapeutics, Inc. (NRIX) Discusses Clinical and Preclinical Updates on BTK, STAT6, and IRAK4 Degrader Programs Transcript

Oct 22, 2025, 7:20 AM EDT - 25 days ago

Nurix Therapeutics Announces $250.0 Million Registered Offering of Common Stock

$Nurix Initiates DAYBreak™ Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia$

Oct 22, 2025, 6:00 AM EDT - 25 days ago

Nurix Initiates DAYBreak™ Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia

Oct 18, 2025, 3:00 AM EDT - 4 weeks ago

Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European Society for Medical Oncology (ESMO) Congress

Oct 11, 2025, 8:13 AM EDT - 5 weeks ago

Nurix: Bexobrutideg Advancement Presses Forward With H2 2025 Milestones

Oct 9, 2025, 4:01 PM EDT - 5 weeks ago

Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Sep 17, 2025, 7:00 AM EDT - 2 months ago

Nurix Therapeutics Presents Preclinical Data from Novel IRAK4 Degrader, GS-6791, Demonstrating Potent Inhibition of IL-1 and IL-36 in Vitro and Efficacy in a Model of Dermatitis

Sep 12, 2025, 9:56 AM EDT - 2 months ago

Nurix Therapeutics, Inc. (NRIX) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)

Sep 12, 2025, 9:43 AM EDT - 2 months ago

Nurix Therapeutics, Inc. (NRIX) Presents At Baird Global Healthcare Conference 2025 (Transcript)

Sep 11, 2025, 3:14 AM EDT - 2 months ago

Nurix Therapeutics, Inc. (NRIX) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript

Sep 10, 2025, 9:42 AM EDT - 2 months ago

Nurix Therapeutics, Inc. (NRIX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Jul 13, 2025, 8:30 AM EDT - 4 months ago

Nurix Therapeutics Could Disrupt BTK Therapy And Reward Investors

Jul 9, 2025, 4:01 PM EDT - 4 months ago

Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Jul 7, 2025, 7:00 AM EDT - 4 months ago

European Medicines Agency Grants Bexobrutideg (NX-5948) Orphan Drug Designation for the Treatment of Lymphoplasmacytic Lymphoma, also Known as Waldenström Macroglobulinemia

Jun 13, 2025, 4:01 PM EDT - 5 months ago

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

$Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM)$

Jun 12, 2025, 7:00 AM EDT - 5 months ago

Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM)

Jun 6, 2025, 7:00 AM EDT - 5 months ago

Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025)

Jun 2, 2025, 7:00 AM EDT - 5 months ago

Sanofi Exercises License Extension Option to Nurix's STAT6 Program

May 28, 2025, 7:00 AM EDT - 6 months ago

Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference

May 15, 2025, 7:00 AM EDT - 6 months ago

Nurix Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference

May 14, 2025, 9:30 AM EDT - 6 months ago

Nurix Therapeutics Announces Presentations of Clinical Data at the 30th European Hematology Association Congress and the 18th International Conference on Malignant Lymphoma

Apr 28, 2025, 4:00 PM EDT - 7 months ago

Nurix Therapeutics Presents Data at the AACR 2025 Annual Meeting Highlighting the Transformative Potential of Its Proprietary DEL-AI Platform Leveraging Machine Learning to Speed the Discovery of Novel Drugs

Apr 25, 2025, 1:00 PM EDT - 7 months ago

Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets

Apr 17, 2025, 5:07 PM EDT - 7 months ago

Nurix Therapeutics: IRAK4 GS-6971 Isn't Only Protein Degrader With Big Potential

Apr 17, 2025, 7:00 AM EDT - 7 months ago

Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory Conditions

Apr 8, 2025, 4:00 PM EDT - 7 months ago

Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update

Apr 2, 2025, 7:00 AM EDT - 8 months ago

Nurix Licenses a Drug Discovery Program to Sanofi Targeting a Novel Transcription Factor for Autoimmune Diseases

Mar 25, 2025, 4:30 PM EDT - 8 months ago

Nurix Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) 2025 Annual Meeting

Mar 17, 2025, 7:00 AM EDT - 8 months ago

Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia

Mar 13, 2025, 4:00 PM EDT - 8 months ago

Nurix Therapeutics Appoints Drug Development Expert Roy D. Baynes, MB.Bch.

Feb 4, 2025, 7:00 AM EST - 10 months ago

Nurix Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 28, 2025, 4:00 PM EST - 10 months ago

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update

Jan 22, 2025, 7:00 AM EST - 10 months ago

Nurix Therapeutics Announces Appointment of John Northcott as Chief Commercial Officer

Jan 9, 2025, 8:44 AM EST - 11 months ago

Nurix Therapeutics: Speculative Bet On BTK Degraders And Targeted Protein Modulation

Jan 6, 2025, 7:00 AM EST - 11 months ago

Nurix Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

$Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom's Macroglobulinemia$

Dec 19, 2024, 7:00 AM EST - 11 months ago

Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom's Macroglobulinemia

Dec 9, 2024, 6:00 PM EST - 1 year ago

Nurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematology Annual Meeting

Dec 2, 2024, 7:00 AM EST - 1 year ago

Nurix Therapeutics Announces Webcast To Review New Data from Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented at the 66th American Society of Hematology (ASH) Annual Meeting

Nov 25, 2024, 7:00 AM EST - 1 year ago

Nurix Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

$Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia$

Nov 20, 2024, 4:00 PM EST - 1 year ago

Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia

Nov 17, 2024, 10:30 AM EST - 1 year ago

Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024

Oct 21, 2024, 4:00 PM EDT - 1 year ago

Nurix Therapeutics Announces Presentations at the 7th Annual TPD & Induced Proximity Summit

$Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom's Macroglobulinemia$

Oct 19, 2024, 8:00 AM EDT - 1 year ago

Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom's Macroglobulinemia

Oct 16, 2024, 4:35 PM EDT - 1 year ago

Nurix Therapeutics Expands Its Board of Directors with the Addition of Drug Commercialization Expert Anil Kapur

Oct 11, 2024, 4:00 PM EDT - 1 year ago

Nurix Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Provides a Corporate Update

Wigglyick Nov. 14 at 10:56 PM

1 · Reply

ellajenkins Nov. 14 at 11:57 AM

0 · Reply

LongTrainRunning Nov. 13 at 4:57 PM

$NRIX this thing is all over the place lately! I'm done accumulating. Now I'll just sit back and wait patiently for a couple of years and do some call trades in the meantime.

1 · Reply

Stmkr Nov. 12 at 3:28 PM

$PRLD $CCCC $NRIX DACs the next big thing in oncology

1 · Reply

SuperGreenToday Nov. 12 at 8:42 AM

0 · Reply

oaksapollo Nov. 8 at 12:37 AM

0 · Reply

nspyre Nov. 7 at 3:19 PM

$NRIX clinical data: IT WORKS! market: DUMP IT 5%!!!!!!!!

1 · Reply

oaksapollo Nov. 5 at 4:45 PM

$NRIX Fidelity 11.5% stake https://ir.nurixtx.com/node/11661/html

2 · Reply

FranciscoJavier2 Nov. 5 at 2:15 AM

1 · Reply

FranciscoJavier2 Nov. 5 at 2:13 AM

1 · Reply

FranciscoJavier2 Nov. 5 at 2:12 AM

The bull thesis is being proven out. Bexobrutideg's >80% ORR is best-in-class, and its unique degradation MOA (addressing scaffolding function) explains its efficacy in inhibitor-resistant patients. The new NX-1607 data is even more impressive: a confirmed Partial Response in MSS CRC, a tumor type known to be unresponsive to checkpoint inhibitors. This is not just another biotech; this is top-tier science delivering results. $NRIX

0 · Reply

JarvisFlow Nov. 4 at 10:47 AM

Needham updates rating for Nurix Therapeutics ( $NRIX ) to Buy, target set at 26.

0 · Reply

JarvisFlow Nov. 4 at 10:40 AM

BTIG has updated their rating for Nurix Therapeutics ( $NRIX ) to Buy with a price target of 27.

0 · Reply

oaksapollo Oct. 30 at 10:04 PM

$NRIX In case anyone is wondering, the stock is likely running because of the 8th annual induced proximity summit which is happening right now. https://proteindegradation.com/ This Nurix DAC deck is pretty exciting: https://www.nurixtx.com/wp-content/uploads/2025/10/TPDs-as-Next-Generation-Antibody-Payloads_Final.pdf Basically they are taking 2 highly selective agents and combining them...so much potential.

1 · Reply

outlawinvestor1 Oct. 26 at 11:57 AM

$CCCC nice updated overview of the tpd landscape. $ARVN $NRIX $GLUE $KYMR

1 · Reply

topstockalerts Oct. 24 at 2:06 PM

Neuraxis Inc announced it has received FDA clearance for its nerve stimulation technology to treat functional abdominal pain. The U.S. Food and Drug Administration granted 510(k) clearance for Neuraxis’ patented percutaneous electrical nerve field stimulation (PENFS) technology. The treatment is approved for functional abdominal pain associated with functional dyspepsia and related nausea symptoms in patients aged 8 and older. This marks the FDA’s first clearance specifically targeting functional dyspepsia in adults. The decision was supported by clinical literature, including randomized controlled trials and real-world evidence demonstrating the therapy’s safety and efficacy. The FDA initially reviewed data from pediatric patients up to 21 years old, then extrapolated findings to support adult use. The expanded indication allows Neuraxis to target the broader general population with its PENFS technology. $NRIX

0 · Reply

mikailoral Oct. 23 at 6:11 PM

$NRIX What do you think will happen?

3 · Reply

oaksapollo Oct. 23 at 3:53 PM

$NRIX 80% PR rate in this patient population, damn impressive: x https://haematologica.org/article/view/12804 Also, WM data: https://haematologica.org/article/view/12758

0 · Reply

NVDAMillionaire Oct. 23 at 3:43 PM

$NRIX Outstanding article that hits the mark on NRIX's current state. So if you want to refresh your NRIX insights or learn about NRIX from scratch, this is a must read. https://beyondspx.com/quote/NRIX/analysis/nurix-therapeutics-pioneering-protein-degradation-for-a-new-era-of-medicine-nasdaq-nrix

0 · Reply

JarvisFlow Oct. 23 at 1:17 PM

Wells Fargo has updated their rating for Nurix Therapeutics ( $NRIX ) to Overweight with a price target of 21.

0 · Reply

JarvisFlow Oct. 23 at 9:57 AM

BTIG updates rating for Nurix Therapeutics ( $NRIX ) to Buy, target set at 35 → 27.

0 · Reply

JarvisFlow Oct. 22 at 5:46 PM

Needham updates rating for Nurix Therapeutics ( $NRIX ) to Buy, target set at 27 → 26.

0 · Reply

Market Cap	984.10M
Revenue (ttm)	54.55M
Net Income (ttm)	-193.57M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-354.85%
Debt to Equity Ratio	0.00

Volume	1,273,300
Avg Vol	1,502,966
Day's Range	N/A - N/A
Shares Out	76.88M
Stochastic %K	73%
Beta	2.30
Analysts	Strong Sell
Price Target	$26.78